NCT00660920View on ClinicalTrials.gov

Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Chronic Myelogenous LeukemiaHematologic Malignancies
Interventions
DRUG

Ponatinib

Comparison of different dosages of drug given orally once per day.

Trial Locations (5)

37203

ARIAD Investigational Site #076, Nashville

48109

ARIAD Investigational Site #011, Ann Arbor

70030

ARIAD Investigational Site #005, Houston

94143

ARIAD Investigational Site #075, San Francisco

97239

ARIAD Investigational Site #048, Portland

Sponsors
All Listed Sponsors
lead

Ariad Pharmaceuticals

INDUSTRY

NCT00660920 - Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies | Biotech Hunter | Biotech Hunter